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Adenovirus antibodies assist HIV
Antibodies against a vaccine vector render T cells more susceptible to HIV-1 infection, say Perreau 
et al. on page 2717. Their results may help explain the failure of a recent HIV vaccine trial.
The HIV-1 vaccine used in Merck’s STEP trial relied on a weakened form of a common cold virus, 
Adenovirus 5 (Ad5), to carry bits of HIV into the body. One worry about the Ad5 vector was that 
widespread immunity to adenoviruses might cause the vaccine to be ousted before an anti-HIV response 
could develop. Instead, there was a chance that vaccine recipients who had circulating antibodies against 
Ad5 were contracting the virus more often, one factor that forced termination of the trial.
Perreau et al. now show that HIV spread through T cell–dendritic cell (DC) co-cultures three 
times as fast when Ad5 and neutralizing antiserum—present in people with prior immunity—was 
added to the cultures. Ad5-antibody complexes triggered DC maturation in the presence of Fc 
receptors (FcR) and Toll-like receptor (TLR)–9. The authors suspect that FcR facilitated the 
uptake of Ad5-antibody complexes into the cell, where viral components could then activate 
TLR9 to trigger DC maturation and activation.
The mature DCs activated both CD4+ and CD8+ T cells, which may have assisted HIV 
infection in two ways. Activated CD4+ cells could provide HIV with more cells to infect. And 
activated Ad5-specifi  c CD8+ T cells could attack infected DCs, thereby reducing the pool of 
DCs presenting HIV antigens. Indeed, weaker HIV-specifi  c CD8 responses were seen in Ad5-
seropositive individuals in response to vaccination.
Merck’s vaccine may have made it to phase 2 trials because nonhuman primates don’t naturally come 
in contact with human adenoviruses, and therefore the potential problem went unrecognized. AM
Acid to remember
A popular epilepsy drug may also be benefi  cial in patients with Alzheimer’s disease (AD), 
if the fi  ndings on page 2781 hold true in clinical trials. Qing et al. improved memory and 
ameliorated brain plaques in mice with an AD-like disease by injecting them with the anti-
seizure drug valproic acid.
Mice with the AD-like disease typically develop amyloid-rich brain plaques after six 
months. When Qing et al. treated the mice with valproic acid soon after plaque formation, 
the plaques shrank and some of the damaged axons in their brains resumed growth. The drug 
also improved performance in memory tests.
The acid worked by inhibiting the activity of glycogen synthase kinase-3 (GSK-3), 
which normally turns on -secretase—the enzyme that cleaves -amyloid precursor proteins. 
Lithium chloride, another drug used in patients with AD, also curbs amyloid- production by 
inhibiting GSK-3 and GSK-3, and has recently been shown to ameliorate axonal damage.
Valproic acid helped mice less as their disease progressed. The authors thus suggest that 
clinical trials should focus on people with early signs of AD. Valproic acid has been given to 
people with AD in the past but, unfortunately, memory improvement was never assessed in 
those studies. AM
Epithelial cells as APCs
Epithelial cells masquerading as antigen-presenting cells (APCs) may lead to autoimmune disease, 
as shown by Ishimaru et al. on page 2915. The findings suggest that Sjögren’s syndrome stems 
from salivary gland epithelial cells that make interferon (IFN)- and then present self-antigens.
During Sjögren’s syndrome, the body’s immune cells attack moisture-producing cells in 
salivary glands and tear ducts. The destruction of these cells is initiated by estrogen loss during 
menopause via the induction of a chromatin-modifying protein called RbAp48, which triggers 
p53-dependent cell death.
The timing of mouse menopause is difficult to pin down, so to better understand RbAp48’s 
role, the group created mice that overexpress RbAp48 in gland cells. They now find that these 
mice develop symptoms resembling Sjögren’s syndrome.
Epithelial cells from transgenic salivary glands produced IL-18 and IFN-, which then induced 
the expression of MHC class II molecules. These cytokines also stimulated the proliferation of 
AD5-antibody complexes (Ad5 IC) 
augment HIV replication in human 
cells.
Valproic acid treatment reduced A 
plaques (arrows) in the brains of mice 
with Alzheimer’s-like disease.
Estrogen loss triggers the production 
of IL-18 (green) and IFN- (red) by 
epithelial cells in human salivary glands.